ClinicalTrials.gg
CompletedNCT01706575Updated Feb 20, 2017Results posted

A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

A Phase 2 interventional study of Pegylated Interferon (Peginterferon) Alfa-2a and Nucleos(t)ide Analogues (NA) in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 27 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-20.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
38th of 59
76 · median 114
Started
2013
with 1 other
Phase 2
5 of 59
none open now
Registered
32nd of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 38th largest by enrollment, is one of 2 that started in 2013, is one of 5 in phase 2, and was the 32nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This open-label, single-arm, multicenter study will evaluate the efficacy and safety of adding Pegasys (peginterferon alfa-2a) to nucleos(t)ide analogue (NAs) treatment in participants with HBeAg-negative chronic hepatitis B genotype D showing stable HBV DNA suppression. After a 12-week Lead-in period on treatment with NA, participants with a HBsAg decline \<0.5 log10 IU/ml will enter the Add-on period to receive Pegasys 180 mcg subcutaneously weekly for 48 weeks in addition to their current NA treatment. Follow-up will be a further 48 weeks, during which the participants will continue their NA treatment.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants, 18 - 65 years of age
  • Chronic
  • Negative for HBeAg
  • On monotherapy with any nucleos(t)ide analogue (NA) but telbivudine at enrolment, and HBV DNA persistently below 20 IU/ml for at least 12 months
  • HBsAg >100 IU/ml at the beginning of the Lead-in phase, confirmed before addition of Pegasys
  • Showing a steady HBsAg kinetic (HBsAg decrease \<0.5 log10 IU/ml from Week -12 to start of the Add-on phase)
  • Negative pregnancy test for women of
  • Women of childbearing potential and fertile males with female partners of childbearing potential must be using reliable during and for 3 months after the Add-on phase

Exclusion criteria

Exclusion Criteria:

  • Coinfection with Hepatitis A virus (HAV), virus (HCV), Hepatitis D virus (HDV), (HIV)
  • Evidence of decompensated liver disease ( >/=6)
  • History or other evidence of a medical condition associated with chronic liver disease (e.g. hemochromatosis, hepatitis, alcoholic liver disease, toxin exposure)
  • Known to peginterferon alfa-2a
  • Pregnant of breastfeeding women
  • Evidence of alcohol and/or drug abuse
  • History of severe psychiatric disease, especially depression
  • History of immunologically mediated disease
  • History or evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
  • History or evidence of severe pulmonary disease associated with functional limitations
  • History of severe cardiac disease
  • History of severe seizure disorder or current anticonvulsant use
  • Evidence of an active or suspected cancer or a history of (other than basocellular carcinoma or in situ cervical carcinoma) within 5 years prior to study entry
  • History of having received any systemic anti-neoplastic (including radiation) or immunomodulatory (including systemic ) treatment \</= 6 months prior to the first dose or the expectation that such a treatment will be needed at any time during the study
  • History or other evidence of severe retinopathy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Pegylated Interferon (Peginterferon) Alfa-2a

    Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than \<0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.

    Drug: Pegylated Interferon (Peginterferon) Alfa-2a · Drug: Nucleos(t)ide Analogues (NA)

Interventions

  • Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.

    Also known as: Pegasys

  • DrugNucleos(t)ide Analogues (NA)

    Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.

06

What researchers measure

Primary outcomes

  1. Efficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48)

    Time frame: Baseline up to Week 48

  2. Efficacy: Percentage of Participants With Serum Hepatitis B Surface Antigen (HBsAg) Decrease >/= 50% From Baseline at End of the Combination Treatment (Week 48)

    Participants who stopped pegylated interferon (PEG-IFN) treatment during the add-on phase due to serum HBsAg loss and HBsAg seroconversion were considered as responders.

    Time frame: Baseline and Week 48

Secondary outcomes

  1. Efficacy: Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at Week 24, 72 and 96

    Change is calculated by HBsAg titer at baseline - HBsAg titer at week of assessments.

    Time frame: Baseline, Week 24, 72 and 96

  2. Efficacy: Percentage of Participants With HBsAg Decrease >/=1 log10 IU/ml From Baseline to Week 48

    Time frame: Baseline, Week 48

  3. Efficacy: Number of Participants With Serum HBsAg Loss at Week 12 That Persisted up to Week 96

    HBsAg loss is defined as HBsAg less than or equal to (\</=) 0.05 IU/ml.

    Time frame: Week 12 up to Week 96

  4. Efficacy: HBsAg Levels According to Interleukin 28B (IL28B) Genotypes

    Time frame: Baseline and Week 48

  5. Efficacy: HBsAg Levels According to Interferon-Inducible Protein 10 (IP-10) Serum Levels

    Time frame: Baseline and Week 48

  6. Safety: Percentage of Participants With Adverse Events (AE)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Baseline up to Week 48

07

Results

Posted Aug 5, 2016

Participant flow

Participant flow — Overall Study
MilestonePegylated Interferon (Peginterferon) Alfa-2a
Started76
Treated70
Completed64
Not completed12
Withdrew: Participant withdrew consent4
Withdrew: Lost to follow-up2
Withdrew: Started but not treated6

Outcome measures

PrimaryEfficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48)
Time frame:
Baseline up to Week 48
Reported as:
Mean · percent change
Efficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48)
percent changePegylated Interferon (Peginterferon) Alfa-2a
Efficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48)59.13 ± 32.14
PrimaryEfficacy: Percentage of Participants With Serum Hepatitis B Surface Antigen (HBsAg) Decrease >/= 50% From Baseline at End of the Combination Treatment (Week 48)

Participants who stopped pegylated interferon (PEG-IFN) treatment during the add-on phase due to serum HBsAg loss and HBsAg seroconversion were considered as responders.

Time frame:
Baseline and Week 48
Reported as:
Number · percentage of participants
Efficacy: Percentage of Participants With Serum Hepatitis B Surface Antigen (HBsAg) Decrease >/= 50% From Baseline at End of the Combination Treatment (Week 48)
percentage of participantsPegylated Interferon (Peginterferon) Alfa-2a
Efficacy: Percentage of Participants With Serum Hepatitis B Surface Antigen (HBsAg) Decrease >/= 50% From Baseline at End of the Combination Treatment (Week 48)67.44
SecondaryEfficacy: Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at Week 24, 72 and 96

Change is calculated by HBsAg titer at baseline - HBsAg titer at week of assessments.

Time frame:
Baseline, Week 24, 72 and 96
Reported as:
Mean · international units per millilitre
Efficacy: Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at Week 24, 72 and 96
international units per millilitrePegylated Interferon (Peginterferon) Alfa-2a
Baseline (n= 56)0 ± 0
Change at Week 24 (n= 56)-546.32 ± 1215.20
Change at Week 72 (n= 55)-815.69 ± 1394.89
Change at Week 96 (n= 55)-728.16 ± 1418.60
SecondaryEfficacy: Percentage of Participants With HBsAg Decrease >/=1 log10 IU/ml From Baseline to Week 48
Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Efficacy: Percentage of Participants With HBsAg Decrease >/=1 log10 IU/ml From Baseline to Week 48
percentage of participantsPegylated Interferon (Peginterferon) Alfa-2a
Efficacy: Percentage of Participants With HBsAg Decrease >/=1 log10 IU/ml From Baseline to Week 4813.95
SecondaryEfficacy: Number of Participants With Serum HBsAg Loss at Week 12 That Persisted up to Week 96

HBsAg loss is defined as HBsAg less than or equal to (\</=) 0.05 IU/ml.

Time frame:
Week 12 up to Week 96
Reported as:
Number · participants
Efficacy: Number of Participants With Serum HBsAg Loss at Week 12 That Persisted up to Week 96
participantsPegylated Interferon (Peginterferon) Alfa-2a
Efficacy: Number of Participants With Serum HBsAg Loss at Week 12 That Persisted up to Week 961
SecondaryEfficacy: HBsAg Levels According to Interleukin 28B (IL28B) Genotypes
Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondaryEfficacy: HBsAg Levels According to Interferon-Inducible Protein 10 (IP-10) Serum Levels
Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondarySafety: Percentage of Participants With Adverse Events (AE)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Baseline up to Week 48
Reported as:
Number · percentage of participants
Safety: Percentage of Participants With Adverse Events (AE)
percentage of participantsPegylated Interferon (Peginterferon) Alfa-2a
Safety: Percentage of Participants With Adverse Events (AE)92.75

Adverse events

Collected over Baseline up to Week 48. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegylated Interferon (Peginterferon) Alfa-2a—5/69 (7.2%)56/69 (81.2%)
Most frequent serious events
Most frequent serious events
EventPegylated Interferon (Peginterferon) Alfa-2a
Papillary thyroid cancerEndocrine disorders1/69
PyrexiaGeneral disorders1/69
Rib fractureInjury, poisoning and procedural complications1/69
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/69
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/69
HemoptysisRespiratory, thoracic and mediastinal disorders1/69
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPegylated Interferon (Peginterferon) Alfa-2a
AstheniaGeneral disorders27/69
HeadacheNervous system disorders19/69
PyrexiaGeneral disorders18/69
MyalgiaMusculoskeletal and connective tissue disorders15/69
Musculoskeletal painMusculoskeletal and connective tissue disorders11/69
ThrombocytopeniaBlood and lymphatic system disorders8/69
InsomniaPsychiatric disorders7/69
Decreased appetiteMetabolism and nutrition disorders6/69
ArthralgiaMusculoskeletal and connective tissue disorders6/69
Back painMusculoskeletal and connective tissue disorders6/69

Baseline characteristics

Lead-in participants included all participants enrolled in lead-in period.

Age, Continuous
Age, Continuous(years)Pegylated Interferon (Peginterferon) Alfa-2a
Mean49.82 ± 8.46
Gender
Gender(Participants)Pegylated Interferon (Peginterferon) Alfa-2a
Female13
Male63
08

Study locations

27 sites
  • Nuovo Policlinico; Dipartimento di Malattie Infettive
    Napoli, Campania 80131, Italy
  • Napoli, Campania 80131, Italy
  • UNI DEGLI STUDI - POLICLINICA S. ORSOLA; Dipartimento Malattie dell'Apparato Digerente e Medicina In
    Bologna, Emilia-Romagna 40138, Italy
  • Bologna, Emilia-Romagna 40138, Italy
  • A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Medica
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Roma, Lazio 00133, Italy
  • Policlinico Umberto I Di Roma
    Roma, Lazio 00161, Italy
  • Roma, Lazio 00161, Italy
  • D.I,M.I.; Cattedra Di Gastroenterologia
    Genova, Liguria 16132, Italy
  • Genova, Liguria 16132, Italy
  • Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia
    Milano, Lombardia 20122, Italy
  • Milano, Lombardia 20122, Italy
  • A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Gastroenterologia
    Torino, Piemonte 10126, Italy
  • Torino, Piemonte 10126, Italy
  • A.O. Universitaria Ospedali Riuniti Di Foggia; Malattie Infettive
    Foggia, Puglia 71100, Italy
  • Foggia, Puglia 71100, Italy
  • A.O. Universitaria Policlinico Monserrato Di Cagliari; Gastroenterologia
    Cagliari, Sardegna 09042, Italy
  • Uni Di Cagliari; Dept. Di Scienze Mediche
    Cagliari, Sardegna 09042, Italy
  • Cagliari, Sardegna 09042, Italy
  • Az. Osp. Uni. Ria Policlinico G. Martino; Dept. Di Med. Interna E Terapia Medica - Ii Clinica Medica
    Messina, Sicilia 98124, Italy
  • Messina, Sicilia 98124, Italy
  • Istituto Di Clinica Medica 1 A; Divisione Di Medicina Generale E Gastroenterologia
    Palermo, Sicilia 90127, Italy
  • Palermo, Sicilia 90127, Italy
  • Ospedale Cisanello - Az. Osp. Pisana; Unità Operativa Di Gastroenterologia Ed Epatologia
    Pisa, Toscana 56124, Italy
  • Pisa, Toscana 56124, Italy
  • Padova, Veneto 35128, Italy
09

References and documents

Publications

  • Lampertico P, Brunetto MR, Craxi A, Gaeta GB, Rizzetto M, Rozzi A, Colombo M; HERMES Study Group. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. J Viral Hepat. 2019 Jan;26(1):118-125. doi: 10.1111/jvh.12999. Epub 2018 Dec 11. PubMed 30187599 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Sep 2013 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2012
First posted
Oct 15, 2012
Start
Jan 2013
Primary completionActual
Sep 2013
CompletionActual
Nov 2014
Results first posted
Aug 5, 2016
Last update
Feb 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01706575
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 15, 2012
Start date
Jan 2013
Primary completion
Sep 2013
Completion
Nov 2014
Results posted
Aug 5, 2016
Last update
Feb 20, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion